Crouse Health Online: Wellness is just a click away.
Share Share
  |  Connect with Us: 
large
med
small
Text Size
 

Health News



Trial Drug Shows Preliminary Promise Against Ovarian Cancer

Trial Drug Shows Preliminary Promise Against Ovarian Cancer

08/22/11

SUNDAY, Aug. 21 (HealthDay News) -- An experimental drug that's shown promise against ovarian cancer caused by mutations in the BRCA1 or BRCA2 genes may also be effective against ovarian cancer not caused by those gene mutations, according to a new study.

Olaparib blocks the activity of a protein called poly ADP ribose polymerase (PARP). Both PARP and BRCA proteins are involved in DNA repair. Clinical trials of olaparib in patients with BRCA 1 and 2 mutations have yielded promising results, the study authors noted.

In the new study, Canadian researchers say they're the first to show that olaparib reduces tumor size in patients with non-hereditary (sporadic) ovarian cancer, which is much more common than BRCA-mutated ovarian cancers.

The phase 2 trial included 65 ovarian cancer patients who received 400 milligrams of olaparib twice daily for four weeks. Measurable tumor shrinkage was seen in 41 percent of patients with BRCA mutations and in 24 percent of those without BRCA mutations, the researchers said.

The study was published online Aug. 21 in The Lancet Oncology.

Side effects were described as mild and included fatigue, nausea, vomiting and decreased appetite, study lead author Karen Gelmon, of the B.C. Cancer Agency in Vancouver, and colleagues said in a news release from the journal.

"This finding not only suggests new therapeutic possibilities for women with this aggressive type of ovarian cancer, but also importantly confirms the hypothesis that subpopulations of patients with common sporadic tumors can be targeted effectively with PARP inhibitor therapy," Dr. Melinda Telli, of Stanford University School of Medicine, wrote in an accompanying editorial.

Another expert agreed. Dr. Stephanie V. Blank is an assistant professor in clinical gynecologic oncology at NYU School of Medicine. She said: "It is extremely exciting that an agent as promising as olaparib can be effective in a broader group of women than had been expected. The next challenge will lie in getting our hands on the drug, which at present is only available for patients on clinical trials."

More information

The American Cancer Society outlines the risk factors for ovarian cancer.

Copyright © 2011 HealthDay. All rights reserved.

Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.

OF INTEREST:
 

Latest News

Crouse First in Area to Perform Single-Site Hysterectomy
more >

MedEx Bedside Prescription Delivery Service

Free service offers convenience, patient education at discharge.
more >

CrouseSports Express After-Hours Ortho Care

Immediate care of orthopedic injuries in kids and adults.
more >

Weight Loss Surgery

Is it right for you? Attend a free information seminar held twice monthly.
more >

Quality at Crouse

See how Crouse Hospital strives to provide the best in patient care.
more >

Cheer Up That Special Someone

Say get well or welcome a new arrival with a gift purchased right at Crouse.

more >

Make an Online Donation Now

Your donation of any amount helps support Crouse services & programs in a meaningful way.
more >

Shop Online Now

Say get well, thinking of you or welcome new baby with a unique gift from the Crouse Gift Shop.

more >